 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...3233343536373839404142...123124» |
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P3 data, Metastases: More on #Lenvatinib & #pembrolizumab in previously treated advanced #endometrialcancer: Updated efficacy and safety from the randomized phase III study 309/ #KEYNOTE-775 in @JCO_ASCO. From @TargetedOnc. #gyncsm @Lenvima_HCP @KEYTRUDA #clinicaltrials (Twitter) - May 2, 2023
- |||| Clinical: Pazopanib, sorafenib, regorafenib, anlotinib, lenvatinib, cabozantinib... Very similar drugs, all with some clinical efficacy reported in osteo- & Ewing sarcoma.. But which one to choose? With @Winette_vdGraaf Myrella we help shed more light into this. https://t.co/NY5KckvWa0 (Twitter) - May 1, 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma. (Pubmed Central) - May 1, 2023
No abstract available
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway. (Pubmed Central) - May 1, 2023
In summary, our data demonstrate that TXN plays a crucial role in HCC stemness and BACH1 plays an integral part in regulating this process by activating the AKT/mTOR pathway. Thus, TXN is a promising target for metastatic HCC therapy.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal: A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma. (Pubmed Central) - May 1, 2023
No new safety signals were observed for any of the treatments. The triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy can convert potentially unresectable HCC into resectable disease and improve long-term survival.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (clinicaltrials.gov) - May 1, 2023
P2, N=40, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
The triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy can convert potentially unresectable HCC into resectable disease and improve long-term survival. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- || Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - May 1, 2023
P1, N=576, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Oct 2024 --> Mar 2024 | Trial primary completion date: Oct 2024 --> Mar 2024
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) (clinicaltrials.gov) - May 1, 2023
P2, N=30, Recruiting, Sponsor: Fudan University
Trial completion date: Oct 2024 --> Mar 2024 | Trial primary completion date: Oct 2024 --> Mar 2024 Not yet recruiting --> Recruiting
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
Journal: Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir. (Pubmed Central) - Apr 29, 2023
Not yet recruiting --> Recruiting Lenvatinib 8
- |||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date: IMbrave251: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (clinicaltrials.gov) - Apr 28, 2023
P3, N=554, Recruiting, Sponsor: Hoffmann-La Roche
Lenvatinib 8 Trial completion date: Feb 2025 --> Sep 2024 | Trial primary completion date: Feb 2025 --> Sep 2024
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) (clinicaltrials.gov) - Apr 28, 2023
P2, N=30, Not yet recruiting, Sponsor: Fudan University
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (clinicaltrials.gov) - Apr 27, 2023
P2, N=35, Not yet recruiting, Sponsor: National Cancer Center, Japan
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5840;
P=N/A
The high rate of recommendation adoption by local treating oncologists suggests this is a valuable service to improve patient care. Outcomes are being collected prospectively in a master observational research protocol to better define clinical utility.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical outcomes in patients with radioiodine refractory thyroid carcinoma treated with dose-reduced lenvatinib. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5725;
Despite an apparently lower response rate, lower doses of lenvatinib can still provide adequate disease control with an acceptable rate of blood pressure and serum creatinine elevation. Weight loss was an almost universal side effect of lenvatinib in this real-world population and was seen at a higher frequency than the historical population.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5722;
Weight loss was an almost universal side effect of lenvatinib in this real-world population and was seen at a higher frequency than the historical population. Overall, PMB was associated with a CR,PR ratio of 5.6% (95% CI 0.01-0.10, I
- Votrient (pazopanib) / Novartis
Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5719;
Pazopanib was associated with durable PFS and good tolerability when offered after PD or intolerance on lenvatinib in this retrospective analysis, warranting a randomized prospective study. >
- Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5710;
Overall response rate is a predictor of PFS and can be used as a surrogate endpoint for the latter (PFS) in RCTs with kinase inhibitors in RAI-refractory DTC, especially when the time to reach PFS data may be protracted, costly, and delayed treatment. The lack of correlations between ORR and PFS or OS in the observational studies may be due to different populations with varying responses, less controlled settings, time to reach OS data, and probably smaller sample sizes.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5632;
This systematic review and meta-analysis reinforce the antitumor activity of the combination of Pembrolizumab and Lenvatinib in patients with advanced or recurrent EC, regardless of MMR status. Despite high rates of serious adverse events related to treatment, most were manageable.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5629;
In this study, we observed that the time to interruption was longer in the higher dose than in the lower dose group. Though we failed to detect a significant differences in PFS/OS, when adjusted for age, we observed a significantly higher HR of progression or death in the lower dose group.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Immunohistochemical expression of ER and p53 as predictive biomarkers of immunotherapy in endometrial cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5628;
Further studies are needed to investigate the role of ER as a predictive biomarker for immunotherapy in EC. >
- Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab usage patterns combined with TKI for mRCC: Financial toxicity and clinical outcomes from self-paying patients in India () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5338;
Treatment de-escalation due to financial toxicity was common and reflects reality in LMICs. Low dose strategies in mRCC warrant evaluation in prospective clinical trials.
- Use of immunotherapy-based combos in advanced renal cell carcinoma in a Galician center. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5336;
There are no statistically significant OS differences between IO-IO & IO-TKI. Immediate or delayed nephrectomy seem safe in selected patients.
- Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5325;
P=N/A
The model tests treatment combinations across multiple modes of action and quantifies cell response including viability, death, migration, infiltration and immune-surveillance. Future work aims to further develop the platform to match/predict patient responses in breast (NCT05435352), kidney, and other tumors.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5320;
Pts with favorable risk, prior nephrectomy or early salvage may have a better treatment response. These observations need to be confirmed in prospective studies.
- The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5310;
The results of our real-world evaluation of prescribing practices in mRCC favoured the use of combination immunotherapy in the first-line setting for the treatment of IMDC intermediate- and poor-risk clear cell mRCC with similar outcomes to the published data in the CheckMate 214 trial. The overall trend towards improved PFS in the first 6 months in our local dataset highlights the importance of patient selection when using immunotherapy.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5206;
This small patient cohort demonstrated preliminary safety and effectiveness of TARE in combination with Atezo/Bev in treating intermediate and advanced stage HCC. Further prospective and comparative studies with large sample sizes are warranted.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A retrospective study exploring the safety and efficacy of hepatic arterial infusion chemotherapy and sequential transarterial embolization combined with lenvatinib and tislelizumab in unresectable hepatocellular carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5194;
P2
Based on the data from this study, a prospective, single-arm Phase II trial is planned. Clinical trial information: NCT05532319.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5193;
P2
Tislelizumab in combination with lenvatinib was well tolerated and showed promising efficacy as a neoadjuvant therapy for resectable HCC with high risk of recurrence. Clinical trial information: NCT04834986.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5186;
Triple therapy with TACE, lenvatinib and PD-1 inhibitors showed promising antitumor activity as well as a tolerable safety profile in patients with ICCA. Larger clinical studies investigating this treatment combination should be considered.
- Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5176;
This study is one of the most significant projects that describes 2nd line treatment patterns post-A+B failure. Further studies are warranted to evaluate larger cohorts to study treatment sequencing in the second and third lines.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Real-world experience with atezolizumab plus bevacizumab in the management of non-resectable hepatocellular carcinoma refractory to first-line systemic therapy: Review of literature. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5172;
Further studies are warranted to evaluate larger cohorts to study treatment sequencing in the second and third lines. Atezolizumab plus Bevacizumab is Safe and effective in the patient
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Therapeutic outcomes of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5168;
However, the likelihood of severe and common adverse events such as hypertension and fatigue are significantly higher after using Lenvatinib than Sorafenib. >
- Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Wuhan Binhui Biotech, Lepu Med, HanX Biopharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Anti-PD1 antibody pucotenlimab () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5165;
P2
This has been confirmed by several phase 3 trials: 1) atezolizumab + bevacizumab showed an ORR of 27.3%, mPFS of 6.8 months, and mOS of 19.2 months in IMbrave150; 2) sintilimab + IBI305 (bevacizumab biosimilar) showed an ORR of 21%, mPFS of 5.6 months and mOS of 22.1 months in Orient-32; 3) camrelizumab + Apatinib showed an ORR of 25.4%, mPFS of 5.6 months and mOS 22.1 months in SHR-1210-III-310. Pucotenlimab plus bevacizumab or lenvatinib has demonstrated clinical efficacy in aHCC patients na
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5146;
The retrospective study was designed to explore the safety and conversion effects of lenvatinib + camrelizumab+ HAIC in potentially resectable HCC. Lenvatinib combined with PD-1 inhibitor and HAIC was well tolerated and showed potential conversion efficacy in the treatment of patients with potentially resectable HCC.
- Stivarga (regorafenib) / Bayer
Efficacy and safety of regorafenib + PD-1 inhibitor combined with local therapy as second-line treatment in patients with advanced hepatocellular carcinoma: A multicenter retrospective real-world study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5145;
3 months. Regorafenib+PD-1 combined with local therapy as the second-line treatment option for advanced HCC may be effective and safe and provides better benefits than regorafenib+PD-1 alone.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Comparative efficacy and safety of anti-PD-1/L1 antibody plus anti-VEGF antibody and anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A systematic review and network meta-analysis. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5135;
The experiments were broadly classified into three groups: anti-PD-1/L1 antibody + anti-VEGF antibody (IMbrave150 and ORIENT-32), anti-PD-1/L1 antibody + VEGFR-targeted tyrosine kinase inhibitor (COSMIC-312, Qin 2022 and LEAP-002) and intermediate reference group (lenvatinib vs sorafenib, REFLECT). The combination of anti-PD-1/L1 antibody and anti-VEGF antibodies has the greatest probability of delivering the longest OS, while anti-PD-1/L1 antibody plus VEGFR-targeted tyrosine kinase inhibitor is correlated with larger PFS benefit at the cost of a lower safety rate.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5134;
TACE combined with lenvatinib and tislelizumab may significantly improve clinical outcomes both compared with TACE alone and TACE combined with lenvatinib with a manageable safety profile for BCLC-B stage uHCC beyond up to seven criteria. Nevertheless, it is necessary to be validated by means of prospective randomized control studies in future.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5132;
Study enrollment is ongoing, more mature data will be presented later. Clinical trial information: ChiCTR2200064384.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5128;
The differences in the initial TME of patients, especially in tumor-infiltrating T lymphocytes, may be potential biomarkers for predicting response and prognosis. This finding provides clues to search for biomarkers for the triple combination therapy of HAIC combined with lenvatinib and PD-1 inhibitors in advanced HCC.
- Baizean (tislelizumab) / BeiGene, Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5125;
This finding provides clues to search for biomarkers for the triple combination therapy of HAIC combined with lenvatinib and PD-1 inhibitors in advanced HCC. Tislelizumab combined with lenvatinib and FOLFOX4-HAIC showed high conversion rate and acceptable toxicity in the treatment of middle-advanced stage HCC, suggesting that this combination could be considered as a new conversion strategy in this population.
- AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Camrelizumab combined with lenvatinib and RALOX-HAIC for hepatocellular carcinoma (HCC) in BCLC stage B and C: A prospective, single-arm, phase II trial (Cal Era study). () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5116;
P2
Combination treatment with camrelizumab and lenvatinib plus RALOX-HAIC showed promising antitumor activity and acceptable toxicity in patients with advanced HCC. Clinical trial information: NCT05003700.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5112;
Clinical trial information: NCT05003700. In selected uHCC patients (without preLRT or treated with lenvatinib as combination), the addition of TACE to ICI+TKI combination therapy can remarkably improve PFS.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Sequential therapy versus first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor therapy for unresectable hepatocellular carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5111;
The patients who had received TKI (lenvatinib or sorafenib) plus ICI (anti-PD-1/PD-L1 monoclonal antibody) as first-line therapy or TKI-(TKI+ICI) sequential therapy were retrospectively included. TKI-(TKI+ICI) sequential therapy is a valid therapeutic strategy for patients with HCC compared with first-line TKI+ICI combination therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical characteristics and initial treatment patterns of patients with HCC in Korea: A multi-center real-world database analysis from the LINK research network. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5105;
The LINK database can serve as a multi-center research platform to facilitate fast and reliable real-world evidence generation for HCC patients. Future updates and subgroup analyses of interest can further evaluate the impact of new therapies and changes to HCC treatment guidelines in Korea.
- Stivarga (regorafenib) / Bayer
Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second?line regimen for patients with unresectable hepatocellular carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5095;
TACE combined with TKI and camrelizumab showed promising clinical benefits. It can effectively control tumor progression and provide opportunities for resection with acceptable safety, which will bring great benefits to uHCC.
- Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Portal hemodynamic effects of different TKIs in patients with advanced hepatocellular carcinoma: A prospective cohort study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4821;
Large sample and long time follow-up research will be necessary to verify their clinical and mechanism effects. >
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
TIPS combined with lenvatinib and PD-1 inhibitor in patients with advanced HCC with symptomatic portal hypertension: A retrospective study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4656;
This retrospective study included thirteen advanced HCC with SPH patients who received TIPS combined with Lenvatinib and PD-1 inhibitor (Tislelizumab/Sintilimab) between January 2020 and January 2023. TIPS combined with Lenvatinib and PD-1 inhibitor demonstrated a valuable anti-cancer strategy for advanced HCC patients with SPH based on the low recurrence rate of SPH and acceptable side effects.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4650;
Gemcitabine + cisplatin has been established as an effective first-line treatment...This study aimed to evaluate the clinical value of biliary intervention combined with the Lenvatinib+PD-1 inhibitor (Tislelizumab/Sintilimab) for the Klatskin tumor... Biliary intervention + ISS combined with the following Lenvatinib+ PD-1 inhibitor is safe and feasible for cholangiocarcinoma patients complicated with obstructive jaundice.
- Stivarga (regorafenib) / Bayer
Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4642;
For patients who are resistant to other TKIs, switching to regorafenib showed good efficacy and manageable safety. Therefore, this treatment protocol can be considered as a potential treatment for patients without clinical benefits after first or second-line combination therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
A phase 2 study of neoadjuvant lenvatinib in locally advanced invasive thyroid cancer. (On Demand | Hall A; Poster Bd # 95a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3880;
P2
The study is currently accruing with 11 patients enrolled at time of submission. Clinical trial information: NCT04321954.